CytomX Therapeutics, Inc.
CTMX
$2.03
$0.031.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 141.10M | 147.56M | 138.10M | 126.62M | 119.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 141.10M | 147.56M | 138.10M | 126.62M | 119.57M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 141.10M | 147.56M | 138.10M | 126.62M | 119.57M |
| SG&A Expenses | 29.63M | 31.40M | 29.73M | 31.93M | 30.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 97.98M | 111.60M | 113.11M | 119.91M | 113.85M |
| Operating Income | 43.13M | 35.96M | 25.00M | 6.71M | 5.72M |
| Income Before Tax | 48.23M | 41.84M | 32.09M | 15.06M | 15.08M |
| Income Tax Expenses | 248.00K | 236.00K | 223.00K | 1.23M | 3.99M |
| Earnings from Continuing Operations | 47.98 | 41.60 | 31.87 | 13.83 | 11.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.98M | 41.60M | 31.87M | 13.83M | 11.09M |
| EBIT | 43.13M | 35.96M | 25.00M | 6.71M | 5.72M |
| EBITDA | 44.70M | 37.65M | 26.76M | 8.55M | 7.62M |
| EPS Basic | 0.56 | 0.48 | 0.38 | 0.17 | 0.14 |
| Normalized Basic EPS | 0.35 | 0.30 | 0.24 | 0.11 | 0.12 |
| EPS Diluted | 0.56 | 0.48 | 0.38 | 0.16 | 0.13 |
| Normalized Diluted EPS | 0.35 | 0.30 | 0.24 | 0.11 | 0.12 |
| Average Basic Shares Outstanding | 387.03M | 342.84M | 337.75M | 333.56M | 329.20M |
| Average Diluted Shares Outstanding | 387.17M | 342.98M | 338.46M | 334.27M | 330.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |